Shares for Schering-Plough rise shortly after FDA approval

NEW YORK The Food and Drug Administration’s recent approval of the increased dosage for Rebetol with Pegintron, raised share prices for Schering-Plough, according to published reports.

The FDA approval was based on a study showing that weight-based dosing of up to 1,400 mg of Rebetol (ribavirin) with Pegintron worked better than with the smaller dose, which was 800 mg.

The combination treatment is used to treat hepatitis C and, according to published reports, its approval has caused the company’s stock to rise 60 cents (3.2 percent), to $19.30.